v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company operates in one operating segment: treatment of respiratory diseases. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision-Maker (the “CODM”), the Company’s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM utilizes the Company’s consolidated financial forecast, which includes product development roadmaps, as a key input to resource allocation. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using the Company’s operating expenses, cash burn and cash runway.
The following table provides significant segment expenses, other segment items, reported segment net loss and a reconciliation of segment net loss to the Company’s total consolidated net loss for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
License and collaboration revenues$2,768 $48 $2,937 $48 
Research and development expense(16,273)(8,773)(31,303)(15,406)
General and administrative expense(4,099)(4,699)(8,845)(9,513)
Other income, net380 580 637 1,809 
Income tax expense(60)(55)(108)(109)
Segment net loss(17,284)(12,899)(36,682)(23,171)
Reconciliation of loss:
Adjustments and reconciling items— — — — 
Consolidated net loss$(17,284)$(12,899)$(36,682)$(23,171)
The Company’s long-lived tangible assets, as well as the Company’s ROU lease assets recognized on the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025 were located as follows: $0.5 million and $0.7 million, respectively, in the U.S. and $3.6 million and $3.8 million, respectively, in the PRC.